Persistent formation of angiotensin II despite treatment with maximally recommended doses of angiotensin converting enzyme inhibitors in patients with chronic heart failure
| Autor: | Edmund H. Sonnenblick, Sam Hanon, Pugazhendi Vijayaraman, Thierry H. Le Jemtel |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Medicine (General)
medicine.medical_specialty Cardiac Output Low Angiotensin-Converting Enzyme Inhibitors 030204 cardiovascular system & hematology Pharmacology Pharmacological treatment 03 medical and health sciences R5-920 0302 clinical medicine Endocrinology Internal medicine Internal Medicine medicine Humans In patient Myocardial infarction Randomized Controlled Trials as Topic Angiotensin II receptor type 1 Dose-Response Relationship Drug biology business.industry Angiotensin II Angiotensin-converting enzyme medicine.disease Heart failure Chronic Disease biology.protein Plasma angiotensin ii business |
| Zdroj: | Journal of the Renin-Angiotensin-Aldosterone System, Vol 1 (2000) |
| ISSN: | 1752-8976 1470-3203 |
| DOI: | 10.3317/jraas.2000.018 |
| Popis: | JRAAS 2000;1:147-50 Introduction Decreasing activation of the renin-angiotensinaldosterone system (RAAS) is an essential target of the pharmacological treatment of patients with congestive heart failure (CHF). Several large, randomised, placebo-controlled trials have shown that angiotensin converting enzyme (ACE) inhibition enhances life expectancy and alleviates symptoms in patients with CHF and with acute myocardial infarction and left ventricular (LV) systolic dysfunction. The exact mechanisms that mediate the clinical benefits of ACE inhibitors are still poorly understood, although it is generally assumed that the benefits are somehow related to decreased activity of the RAAS and thereby reduced levels of tissue and plasma angiotensin II (Ang II). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|